Abstract

8-Cl-cAMP, a site-selective cAMP analog, induces growth inhibition in a variety of cell types of human cancer cell lines. This inhibitory effect of 8-Cl-cAMP was related to its ability to differentially regulate type I versus type II cAMP-dependent protein kinase. In the present study we demonstrated a unique mechanism of action of 8-Cl-cAMP in the regulation of these kinase isozymes in HL-60 human promyelocytic leukemia cells. High-performance liquid chromatography (HPLC) resolved various isoforms of protein kinase present in HL-60 cells. In control cells, type I protein kinase (PKI) comprised more than 90% and type II protein kinase (PKII) less than 10% of the total cAMP-stimulated kinase activity. Treatment with 8-Cl-cAMP (5 microM, 72 h) decreased PKI to a level below 30% of that in untreated control cells and markedly increased PKII composed of three peaks. Photoaffinity labeling/SDS-polyacrylamide gel electrophoresis of column fractions identified the molecular species of regulatory (R) subunits present in protein kinases. Control cells contained high levels of the 48-kDa protein (RI) that composed PKI and low levels of the 50-kDa RII associated with PKII. 8-Cl-cAMP treatment brought about a decrease in the 48-kDa RI along with an increased formation of the truncated 34-kDa RI associated with PKI and an increase in the 50-54-kDa species of RII associated with PKII. A similar protein kinase profile as that shown by 8-Cl-cAMP treatment was observed in cells infected with the human RII beta retroviral vector: the 48-kDa RI of PKI decreased and the 52- and 54-kDa RII associated with PKII increased as compared with uninfected control cells. However, unlike 8-Cl-cAMP treatment, RII beta retroviral vector infection brought about no increase in the 34-kDa-truncated RI but exhibited an increase in the free 48-kDa RI subunit. As the 48-kDa RI and the 50-kDa RII were present in control cells, the enhanced expression of the 52- and 54-kDa RII proteins was due to overexpression of the RII beta gene. We identified the 48-kDa RI as RI alpha, the 50-kDa RII as RII alpha, the 52-kDa RII as RII beta, and the 54-kDa RII as the phosphorylated form of either the RII alpha or RII beta subunit. In vivo labeling experiments using [3H]8-Cl-cAMP demonstrated that 8-Cl-cAMP enters cells and binds to both PKI and PKII.(ABSTRACT TRUNCATED AT 400 WORDS)

Highlights

  • 8-Cl-cAMP, a site-selective cAMP analog, induces PKII

  • The tetrameric protein kinase is kDa RII associated with PKII. 8-Cl-CAMP treatment composed of two C subunits’ bound to a R subunit dimer

  • Differential Regulation of CAMP-dependent Protein Kinase 8-Cl-CAMP.Cell extracts were fractionated by anion-exchange chro

Read more

Summary

Inmammalian cells cAMPactsthroughbindingtoits

Control cells contained high levelosf the 48-kDa pro- receptor protein, CAMP-dependent protein kinase (reviewed tein (RI) that composed PKI and low levels of the 50- by Krebs and Beavo, 1979). NIH3T3 cells (Jahnsen et al, 1986; @yen et al, 1988; Cadd the role of these regulatory subunits in the regulation of and McKnight, 1989; Otten et al, 1991), and its enhanced protein kinase holoenzyme. Methods ter (1984) and Cho-Chung (1990)) suggest distinct roles for protein kinase isozymes in growth control It was shown (Cho-Chung et al, 1989)that differential regulation of. The strikinggrowth buffer A (20 mM potassium phosphate (pH 6.8), 2 mM EDTA, 1mM inhibitory effect of 8-Cl-CAMPhas been related (Ally et al, 1988;Cho-Chung, 1990)to itsselective binding and activation of protein kinase isozymes: 8-C1-CAMPbinds to PKII with a high affinity for site B but with a low affinity for site A of RII, keeping PKII in the holoenzyme form, while binding. A computer program written in Turbo Pascal (RNAnalysis by Etienne Lamoreaux)for the Macintosh computer generated standard curvesfor the dilutions (Hollander and Fornace1, 989)

RESULTS
TypaTenydpI e
DISCUSSION
Type I and Type II KinIassoeenzGymirnoews th Control
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call